​

Abbott Laboratories (ABT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABT Stock Forecast

Abbott Laboratories (ABT) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $131.00, with a high of $135.00 and a low of $125.00. This represents a 1.00% increase from the last price of $129.70.

$100 $107 $114 $121 $128 $135 High: $135 Avg: $131 Low: $125 Last Closed Price: $129.7

ABT Stock Rating

Abbott Laboratories stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (75.00%), 9 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 0 9 27 Strong Sell Sell Hold Buy Strong Buy

ABT Price Target Upside V Benchmarks

TypeNameUpside
StockAbbott Laboratories1.00%
SectorHealthcare Stocks 33.91%
IndustryMedical Device Stocks20.97%

Price Target Trends

1M3M12M
# Anlaysts--22
Avg Price Target--$125.71
Last Closing Price$129.70$129.70$129.70
Upside/Downside---3.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 257137--27
Mar, 258135-127
Feb, 258134-126
Jan, 258136-128
Dec, 248135-127
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 08, 2025Lee HambrightBernstein$135.00$114.2518.16%4.09%
Oct 17, 2024Adam MaederPiper Sandler$133.00$117.8212.88%2.54%
Oct 17, 2024Lee HambrightBernstein$138.00$117.8217.13%6.40%
Oct 16, 2024Matthew TaylorJefferies$125.00$117.826.09%-3.62%
Oct 16, 2024Vijay KumarEvercore ISI$128.00$117.828.64%-1.31%
Oct 16, 2024Marie ThibaultBTIG$139.00$117.8217.98%7.17%
Oct 08, 2024Suraj KaliaOppenheimer$130.00$114.3013.74%0.23%
Oct 08, 2024Charles MinervinoSusquehanna$120.00$114.304.99%-7.48%
Oct 08, 2024Shagun SinghRBC Capital$130.00$113.3614.68%0.23%
Sep 19, 2024Scott FortuneRoth Capital$24.01$54.49-55.94%-81.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2025RBC CapitalOutperformOutperformhold
Mar 04, 2025CitigroupBuyBuyhold
Jan 27, 2025BarclaysOverweightOverweighthold
Jan 23, 2025UBSBuyBuyhold
Jan 08, 2025BernsteinOutperformOutperformhold
Jan 02, 2025Evercore ISIOutperformOutperformhold
Oct 17, 2024William BlairOutperformOutperformhold
Oct 17, 2024Piper SandlerOverweightOverweighthold
Oct 17, 2024UBSBuyBuyhold
Oct 17, 2024BernsteinOutperformOutperformhold

Financial Forecast

EPS Forecast

$2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$2.52$3.97$3.94$3.30$7.67-----
Avg Forecast$3.55$5.10$5.23$4.44$4.67$5.16$5.70$6.30$6.92$7.60
High Forecast$3.59$5.15$5.29$4.45$4.68$5.21$6.13$6.99$7.14$7.84
Low Forecast$3.52$5.05$5.16$4.43$4.66$5.08$5.49$5.55$6.82$7.49
Surprise %-29.01%-22.16%-24.67%-25.68%64.24%-----

Revenue Forecast

$30B $36B $42B $48B $54B $60B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$34.61B$43.08B$43.65B$40.11B$41.95B-----
Avg Forecast$33.85B$42.32B$43.22B$40.08B$42.00B$44.38B$47.66B$51.09B$54.53B$58.49B
High Forecast$34.13B$42.66B$43.58B$40.26B$42.08B$45.00B$48.69B$51.13B$55.85B$59.91B
Low Forecast$33.59B$41.99B$42.75B$39.95B$41.87B$44.24B$47.22B$51.04B$53.94B$57.86B
Surprise %2.24%1.79%0.99%0.08%-0.12%-----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$4.50B$7.07B$6.93B$5.72B$13.40B-----
Avg Forecast$3.98B$5.75B$6.73B$5.70B$8.18B$8.99B$10.17B$10.96B$12.10B$13.29B
High Forecast$4.78B$6.90B$8.07B$6.84B$8.19B$9.10B$10.72B$12.22B$12.48B$13.71B
Low Forecast$3.18B$4.60B$5.38B$4.56B$8.16B$8.88B$9.61B$9.71B$11.93B$13.11B
Surprise %12.93%23.04%3.03%0.39%63.92%-----

ABT Forecast FAQ

Is Abbott Laboratories stock a buy?

Abbott Laboratories stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Abbott Laboratories is a favorable investment for most analysts.

What is Abbott Laboratories's price target?

Abbott Laboratories's price target, set by 36 Wall Street analysts, averages $131 over the next 12 months. The price target range spans from $125 at the low end to $135 at the high end, suggesting a potential 1.00% change from the previous closing price of $129.7.

How does Abbott Laboratories stock forecast compare to its benchmarks?

Abbott Laboratories's stock forecast shows a 1.00% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the medical device stocks industry (20.97%).

What is the breakdown of analyst ratings for Abbott Laboratories over the past three months?

  • April 2025: 25.93% Strong Buy, 48.15% Buy, 25.93% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 29.63% Strong Buy, 48.15% Buy, 18.52% Hold, 0% Sell, 3.70% Strong Sell.
  • February 2025: 30.77% Strong Buy, 50.00% Buy, 15.38% Hold, 0% Sell, 3.85% Strong Sell.

What is Abbott Laboratories’s EPS forecast?

Abbott Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $5.16, marking a -32.72% decrease from the reported $7.67 in 2024. Estimates for the following years are $5.7 in 2026, $6.3 in 2027, $6.92 in 2028, and $7.6 in 2029.

What is Abbott Laboratories’s revenue forecast?

Abbott Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $44.38B, reflecting a 5.79% increase from the reported $41.95B in 2024. The forecast for 2026 is $47.66B, followed by $51.09B for 2027, $54.53B for 2028, and $58.49B for 2029.

What is Abbott Laboratories’s net income forecast?

Abbott Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $8.99B, representing a -32.91% decrease from the reported $13.4B in 2024. Projections indicate $10.17B in 2026, $10.96B in 2027, $12.1B in 2028, and $13.29B in 2029.